Announcing the ASCO Genitourinary Cancers Symposium Featured Voices! Follow along for a range of expert insights and join the conversation using the official hashtag: #GU25 Not yet registered? There’s still time to join us in person or online:

A heartfelt celebration of life for @felixfengmd, honoring his incredible legacy & dedication to cancer research. In his memory, we will continue the ‘Felix Feng Endowed @ConquerCancerFd YIA in Prostate Cancer Research,’ ensuring his impact continues for future generations. #GU25

RT @MikeSerzanMD: 👥Case-Based Session: Evolving Landscape of the Management of Oligometastatic Disease #GU25 🐺Dr @ChadTangMD presenting Ab…

Amazing keynote by Dr. @billdahutmd of @AmericanCancer on driving innovation in patient-centered care, including the role of AI. #GU25

Don’t forget to visit our exhibitors on the first floor and check out Artificial Intelligence for Oncologists: A Hands-On Experience on the third floor! #GU25

Don’t miss our #GU25 Keynote with Dr. @billdahutmd from @AmericanCancer! He’ll explore how creative innovation is driving science forward to improve patient-centered care.

Read a plain language summary of breaking news research from #GU25: Results from a mobile #ProstateCancer screening clinic in the UK ➡️

RT @ReginaBarCar: Need a place for an early-morning or mid-session recharge? These are must-tries! #GU25 #OncoTwitter ☕ Coffee First! Best…

Great session covering radiation response predictions to treatment comparisons in high-risk prostate cancer, and more! What stood out to you? Share your key takeaways!

New from #GU25: Final TALAPRO-2 results reveal a statistically significant & clinically meaningful improvement in survival w/ 1L talazoparib + enzalutamide, both in pts w/ HRR-deficient mCRPC & in all-comers: #ASCODailyNews @neerajaiims @TDorffOnc

RT @MikeSerzanMD: 🗣️Prostate Cancer Oral Abstracts #GU25 Dr David Fisher presenting Abs20: Which patients with mHSPC benefit more from ARP…

RT @ReginaBarCar: #GU25 bites en Español🌮 🧬 PORTOS: ¿Puede un biomarcador predecir la respuesta a la RT? 🔹 ¿Quién? Pacientes con CPa-AR tra…

RT @ReginaBarCar: Be like @TDorffOnc @cityofhope ➡️Thoughtful and balanced discussion ✅ ➡️ Call for more diversity in clinical trials ✅ ➡️…

RT @crisbergerot: Exploring the impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer. 📊 Final 10-year…

RT @yekeduz_emre: Let's get started! @ASCO #GU25 @OncoAlert @DanaFarber_GU @ConquerCancerFd @ASCOPost @ASCOTECAG #cancer #Oncology https:…

In our latest “Science in Seconds” Dr. @BradMcG04 discusses 2 abstracts findings from phase 3 TALAPRO-2 trial highlighting final OS w TALA + ENZA as 1st-line Tx: 1 for unselected pts w #mCRPC & 1 for pts w HRR-deficient mCRPC. #GU25

Breaking #ProstateCancer news: Drug combination of talazoparib & enzalutamide helps #mCRPC patients with and without HRR gene alterations live longer compared to enzalumatide alone. Read a plain language summary of the #TALAPRO trial presented at #GU25:

Heading over to the first session of the day: Oral Abstract Session A: Prostate Cancer #GU25

Supplement your #GU25 experience with #ASCOEdBook review articles: #OncTwitter

Welcome to #GU25! Now that the Symposium has begun, stay up to date on the latest from San Francisco with #ASCODailyNews! Read in-depth coverage of newly presented prostate, kidney, and bladder cancer research here:

Welcome to #GU25! This year, we’re bringing together leading experts, researchers, and clinicians to share the latest advancements in GU cancer care. From groundbreaking research to innovative treatment strategies, #GU25 is the place to connect, collaborate, and drive progress.